What Is The Long-term Outlook for AMC Stock?
Meme stock extraordinaire AMC Entertainment Holdings, Inc. (NYSE:AMC) has long…
Buy
61
MLTX Quote, Financials, Valuation and Earnings
Last price:
$47.39
Seasonality move
:
43.23%
Day range:
$45.49 - $47.43
52-week range:
$31.42 - $58.26
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
7.13x
Volume:
267.6K
Avg. volume:
552.9K
1-year change:
19.32%
Market cap:
$2.9B
Revenue:
--
EPS (TTM):
-$2.30
Earnings Data
Next earnings date for MLTX
Aug 07
2025
Most recent earnings per share
-$0.63
Beat by $0.11
(May 12/2025)
Consensus Estimate
-$0.74
(May 12/2025)
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
MLTX Quarterly Earnings History
| Date | Quarter | Revenue Forecast | Actual Revenue | Reported EPS | Consensus EPS | Beat/Miss |
|---|---|---|---|---|---|---|
| 08/07/2025 | Q2 | -- | -- | -- | -$0.76 | -- |
| 05/12/2025 | Q1 | -- | -- | -$0.63 | -$0.74 | $0.11 |
| 02/26/2025 | Q4 | -- | -- | -$0.72 | -$0.59 | -$0.13 |
| 11/07/2024 | Q3 | -- | -- | -$0.56 | -$0.45 | -$0.11 |
| 08/07/2024 | Q2 | -- | -- | -$0.39 | -$0.28 | -$0.11 |
| 05/07/2024 | Q1 | -- | -- | -$0.22 | -$0.21 | -$0.01 |
| 02/29/2024 | Q4 | -- | -- | -$0.10 | -$0.27 | $0.17 |
| 11/14/2023 | Q3 | -- | -- | -$0.18 | -$0.25 | $0.07 |
| 08/10/2023 | Q2 | -- | -- | -$0.23 | -$0.29 | $0.06 |
| 05/11/2023 | Q1 | -- | -- | -$0.23 | -$0.29 | $0.06 |
| 03/20/2023 | Q4 | -- | -- | -$0.31 | -$0.28 | -$0.03 |
| 11/14/2022 | Q3 | -- | -- | -$0.27 | -- | -- |
| 08/12/2022 | Q2 | -- | -- | -$0.34 | -- | -- |
| 03/31/2022 | Q1 | -- | -- | -$0.43 | -- | -- |
| 09/30/2021 | Q3 | -- | -- | -$0.17 | -- | -- |
| 06/30/2021 | Q2 | -- | -- | -$0.89 | -- | -- |
MoonLake Immunotherapeutics Earnings Questions
-
How Much did MoonLake Immunotherapeutics Generate in Revenue Last Quarter?
MoonLake Immunotherapeutics reported -- worth of top line sales in its most recent quarter.
-
Did MoonLake Immunotherapeutics Beat Earnings Last Quarter?
MoonLake Immunotherapeutics announced earnings per share of -$0.63 which represents a beat of analyst forecast a -$0.74 per share.
-
Is MoonLake Immunotherapeutics Profitable?
MoonLake Immunotherapeutics reported -- that represents -- per share over the last quarter.
-
What is the Analyst Consensus for MoonLake Immunotherapeutics EPS Next Year?
MoonLake Immunotherapeutics's earnings are forecast to decrease from -$1.89 per share to -$1.72 per share next year representing a decrease of -57.46%.
-
When is MoonLake Immunotherapeutics's Earnings Date?
MoonLake Immunotherapeutics's next earnings date is August 7, 2025.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is NuScale the Best Nuclear Stock to Buy?
NuScale Power (NYSE:SMR) is a nuclear power startup that has…
Where Will Kestra Medical Stock Be in 1 Year?
Kestra Medical Technologies (NASDAQ:KMTS) is a medical device startup that…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 42x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 50x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
55
AMBA alert for Jun 26
Ambarella [AMBA] is up 4.36% over the past day.
Buy
54
EXOD alert for Jun 26
Exodus Movement [EXOD] is down 9.63% over the past day.
Buy
78
SMR alert for Jun 26
NuScale Power [SMR] is down 10.59% over the past day.
